| Title | Spotlight on alemtuzumab. | | Author(s) | Jones J, Coles A | | Institution | Department of Clinical Neurosciences, Box 165, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK Phone: +44 (0) 1223 217842 Fax: +44 (0) 1223 216571, E-mail: jls53@medschl.cam.ac.uk. | | Source | Int MS J 2009 Sep; 16(3):77-81. | | Abstract | Alemtuzumab, formally known as Campath-1H, is a humanized monoclonal antibody directed against CD52, a protein on the surface of lymphocytes and monocytes with unknown function. A single dose of alemtuzumab leads to a rapid, profound and prolonged lymphopenia. A Phase II trial has shown that alemtuzumab reduces the risk of relapse and accumulation of disability by over 70% compared with interferon beta in patients with early relapsing-remitting multiple sclerosis (MS). Alemtuzumab has been used in Cambridge as an experimental treatment for MS since 1991. In this review we summarize our experience; describing how this prototypical, "bench-to-bedside" therapy continues to inform basic science, revealing aspects of the pathogenesis of MS and lymphopeniaassociated autoimmunity. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19878629 |
|
